TradingViewTradingView

eXoZymes 3Q 2026: EPS ($0.24) — 10-Q Summary

Czytanie zajmuje mniej niż 1 minutę

eXoZymes reported no operating income in the quarter, unchanged from a year earlier, while its net loss narrowed 2.1%. Higher research and development costs, driven by salaries, bonuses, stock-based compensation, laboratory expenses and reduced grant funding, were largely offset by a gain from remeasuring warrant liabilities.

Financial Highlights

MetricCurrent quarterPrior year quarterYoY change
Net income²($2.24M)($2.29M)2.1%
Diluted EPS³($0.24)($0.27)11.1%

² Reported as “Net loss”. ³ Reported as “Net loss per common share – basic and diluted”.

Business Highlights

  • NCT pilot: The 100-liter pilot run converted 99% of feedstock into end product at 99.6% purity, the company said.
  • Pipeline: AMBER is in scale-up, GRAS work and clinical studies; SAPPHIRE has begun scale-up, while AMETHYST completed proof of concept.
  • DOE selection: In July, eXoZymes was selected for the Genesis Mission to develop AI-powered digital twins with Lawrence Berkeley National Laboratory.
  • Funding outlook: Management said current working capital is insufficient to fund operations for 12 months from issuance and substantial doubt exists about going concern.

Original SEC Filing: EXOZYMES INC. [ EXOZ ] - 10-Q - Nov. 13, 2026

Wyłączenie odpowiedzialności